A previously developed bio safe transmissible gastroenteritis virus (TGEV) -based vector will be engineered to amplify foot-and-mouth disease cased proteins, to serve as a marked vaccine against FMD. In addition to the bio safety features of the TGEV-based vector, constructions will include exclusively FMDV protease JC and P1-2A (to produce virus-like particles in situate and or a fragment of 3D so that no FMDV can be produced. The TGEV chosen replicates in the enteric and respiratory tracts which are very adequate replication in the enteric and respiratory Antigen expression, immune responses, protection against challenge with virulentFMDV, and possible virus transmission after challenge will be examined using swine, one of the major animal hosts for FMDV. Constructs expressing 20 amino acid sequences of the major antigenic site of FMDV-O and FMDV-C will also be tested in an attempt to broader the immune response.
Funding SchemeCSC - Cost-sharing contracts
17813 Vall De Bianya
17498 Insel Riems
8200 AB Lelystad
GU24 0NF Woking